In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 1448-87-9, name is 2-Chloroquinoxaline, introducing its new discovery. Product Details of 1448-87-9
HETEROCYCLIC LIPXON ANALOGS AND USES THEROF
The present invention relates to a compound of formula (I): wherein L is an optionally substituted heterocyclic group excluding unsubstituted monocyclic pyridine groups; wherein a is 0, 1 or 2; wherein R1 is H or with R2 is a bond; wherein R2 is an optionally substituted alkoxy or aryloxy group, or with R1 forms a bond; wherein R3 is an optionally substituted alkyl group; and wherein R4 is CH2, CMe2 or O. Such compounds may be used in the treatment or prophylaxis of a disease or condition in which inhibition of acute inflammation and/or promotion of its resolution and/or suppression of fibrosis.
We’ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 1448-87-9, and how the biochemistry of the body works.Product Details of 1448-87-9
Reference：
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N507 | ChemSpider